期刊文献+

康柏西普玻璃体腔注射对糖尿病视网膜病变患者视力的影响 被引量:8

下载PDF
导出
摘要 目的分析糖尿病视网膜病变患者利用康柏西普玻璃体腔注射对其视力的影响。方法选取我院2013年4月至2014年4月收治的糖尿病视网膜病变患者70例70眼为研究对象,随机分为2组,对照组给予曲安奈德注射治疗,观察组给予康柏西普注射治疗,比较分析2组治疗后视力变化情况。结果观察组视力恢复效果优于对照组,不良反应发生率低于对照组,生活质量高于对照组。结论康柏西普玻璃体腔注射用于糖尿病视网膜病变患者的治疗中,能显著提高患者视力,提高患者生活自理能力,有临床推广价值。
作者 施航
出处 《中国医药指南》 2017年第27期173-174,共2页 Guide of China Medicine
  • 相关文献

参考文献5

二级参考文献42

  • 1Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis [J]. Ophthalmology, 2012, 119(3): 571-580.
  • 2American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern? Guidelines: comprehensive adult medical eye evaluation E EB/OL]. San Francisco: American Academy of Ophthalmology, 2010 [ 2010-09-11 ]. http://one. Aao. Org/ CE/ Practice Guidelines/ PPP. Asox? o: 1.
  • 3Takashi U, Yasuo N, Takuhiro Y, et al. Systemic vascular safety of ranibizumah for age-related macular degeneration: systematic review and meta-analysis of randomized trials [J]. Ophthalmology, 2014, 121(11) :2193-2203.
  • 4Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration [J]. Clin Ophthalmol, 2008, 2(2) :377-388.
  • 5Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12- month randomized phase 2 study: AURORA study [J]. Ophthalmology, 2014, 121(9) :1740-1747.
  • 6Wang Q, Li T,Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8) : 70544[2013-08-12]. http://dx, plos. org/10. 1371/ journal, pone. 0070544.
  • 7Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration [J]. N Engl J Med, 2006, 355:1419-1431.
  • 8Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study [J]. Ophthalmology, 2009, 116(1) :57-65.
  • 9Singer MA, Awh CC, Sadda S, et al. HORIZON: an openlabel extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration [J]. Ophthalmology, 2012, 119(6) :1175-1183.
  • 10Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)[J]. Ophthalmology, 2013, 120(11) : 2292-2299.

共引文献134

同被引文献52

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部